| Project/Area Number |
17K10834
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Keywords | 脳出血 / デフェロキサミン / 脳浮腫 / 脳萎縮 / 高血圧性脳出血 / 鉄 / deferoxamine / 二次的脳損傷 |
|---|
| Outline of Final Research Achievements |
We investigated whether Deferoxamine (DFX) is effective on brain injury after ICH in SD rats.Autologous whole blood (100 μL) was injected into the right basal ganglia. We explored optimal DFX dose, potential therapeutic time windows, and optimal therapeutic durations. DFX can reduce ICH-induced brain injury in rats and that a dose 50mg/kg is the optimal dose of DFX. DFX administration, when begun within 12 hours after ICH, reduced brain edema. DFX treatment started 2 hours after ICH and administrated for 7 days attenuated ICH-induced brain atrophy and neurological deficits. DFX attenuated brain atrophy and neurological deficits when begun within 24 hours and administrated for 7 days.
|
| Academic Significance and Societal Importance of the Research Achievements |
脳出血後の脳浮腫、脳萎縮および神経脱落症状は、患者の予後を左右する重大な因子である。鉄キレート剤であるDFXは脳出血後の脳損傷を改善できることが示唆された。本実験にてDFXの適切な濃度、投与期間、投与タイミングを示した。このデータは、今後脳出血に対するDFX治療が臨床応用されていく上で非常に重要である。
|
